



ProAir[®] HFA (albuterol) – First-time generic

- On January 17, 2019, Teva launched an authorized generic version of [ProAir HFA \(albuterol\)](#) inhalation aerosol.
 - Teva Respiratory also markets the branded version of ProAir HFA.
- ProAir HFA is approved for the treatment or prevention of bronchospasm in patients aged 4 years and older with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm in patients aged 4 years and older.
- Albuterol is also available generically as oral [tablets](#), oral [extended-release tablets](#), oral [syrup](#), inhalation nebulizer [solution](#), inhalation [aerosol](#) and combination [ipratropium/albuterol](#) inhalation solution, and as a branded inhalation aerosol ([Proventil[®] HFA](#)) and inhalation powder ([ProAir Respiclick[®]](#)).
 - Albuterol tablets and extended-release tablets are approved for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease.
 - Albuterol syrup is approved for the relief of bronchospasm in adults and children 2 years of age and older with reversible obstructive airway disease.
 - Albuterol nebulizer solution is approved for the relief of bronchospasm in patients 2 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm.
 - Ipratropium/albuterol is approved for the treatment of bronchospasm associated with chronic obstructive pulmonary disease in patients requiring more than one bronchodilator.
 - Generic inhalation aerosol, Proventil HFA and ProAir Respiclick carry the same indications as ProAir HFA.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.